-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Renal cell carcinoma is a kind of clinically heterogeneous malignant tumors, which often metastasize widely and progress rapidly
.
Patients with oligometastasis usually have a blunt clinical course
This is a single-arm, phase 2 feasibility trial that recruits renal cell carcinoma patients who are 18 years of age or older, with no more than 5 metastatic lesions, ECOG performance status 0-2, and previous systemic treatment ≤1 times
.
The patient received whole body stereotactic radiotherapy (defined as ≤5 times, each time ≥7 Gy) to treat all the lesions, and the systemic treatment was suspended
Progression-free survival
From July 13, 2018 to September 18, 2020, a total of 30 patients (6 [20%] women) were recruited
.
All patients had clear cell carcinoma and had undergone nephrectomy before enrollment
The patients were followed up for 17.
Survival without system treatment
In summary, sequential radiotherapy may help delay the start of systemic treatment and may allow patients with specific oligometastatic renal cell carcinoma to continue to interrupt systemic treatment
Sequential radiotherapy may help delay the start of systemic treatment and may allow patients with specific oligometastatic renal cell carcinoma to continue to interrupt systemic treatment.
Original source:
Chad Tang, et al.
Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial in this message
